Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems

Anacak, Yavuz; Yalman, Deniz; Özsaran, Zeynep; Haydaroğlu, Ayfer

doi:10.1016/s0360-3016(01)01527-9

Cited by 53 publications

(28 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although an excess of bladder side effects was seen at this time point, they did not reach statistical significance; however, on further follow-up, the differences in bladder toxicity became more obvious and statistically significant for the margin randomisation. In general, the LENT SOM assessments gave similar findings to the RTOG assessments as reported by other groups (Anacak et al, 2001), although the LENT SOM assessment was more sensitive at picking up minor degrees of bladder impairment, which were seen in both the 74 Gy and 1.5 cm margin groups. It is noteworthy that after treatment, the degree of bladder dysfunction was decreased from pretreatment assessments, probably reflecting the improvement in lower urinary tract symptoms as a result of prostate gland shrinkage.…”

Section: Discussionsupporting

confidence: 79%

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

et al. 2005

View full text Add to dashboard Cite

Radical radiotherapy is a standard form of management of localised prostate cancer. Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose escalation. We have tested the effects on tumour control and side effects of escalating radiotherapy dose and investigated the appropriate target volume margin. After an initial 3 -6 month period of androgen suppression, 126 men were randomised and treated with radiotherapy using a 2 by 2 factorial trial design. The initial radiotherapy tumour target volume included the prostate and base of seminal vesicles (SV) or complete SV depending on SV involvement risk. Treatments were randomised to deliver a dose of 64 Gy with either a 1.0 or 1.5 cm margin around the tumour volume (1.0 and 1.5 cm margin groups) and also to treat either with or without a 10 Gy boost to the prostate alone with no additional margin (64 and 74 Gy groups). Tumour control was monitored by prostate-specific antigen (PSA) testing and clinical examination with additional tests as appropriate. Acute and late side effects of treatment were measured using the Radiation Treatment and Oncology Groups (RTOG) and LENT SOM systems. The results showed that freedom from PSA failure was higher in the 74 Gy group compared to the 64 Gy group, but this did not reach conventional levels of statistical significance with 5-year actuarial control rates of 71% (95% CI 58 -81%) in the 74 Gy group vs 59% (95% CI 45 -70%) in the 64 Gy group. There were 23 failures in the 74Gy group and 33 in the 64 Gy group (Hazard ratio 0.64, 95% CI 0.38 -1.10, P ¼ 0.10). No difference in disease control was seen between the 1.0 and 1.5 cm margin groups (5-year actuarial control rates 67%, 95% CI 53 -77% vs 63%, 95% CI 50 -74%) with 28 events in each group (Hazard ratio 0.97, 95% CI 0.50 -1.86, P ¼ 0.94). Acute side effects were generally mild and 18 weeks after treatment, only four and five of the 126 men had persistent XGrade 1 bowel or bladder side effects, respectively. Statistically significant increases in acute bladder side effects were seen after treatment in the men receiving 74 Gy (P ¼ 0.006), and increases in both acute bowel side effects during treatment (P ¼ 0.05) and acute bladder sequelae (P ¼ 0.002) were recorded for men in the 1.5 cm margin group. While statistically significant, these differences were of short duration and of doubtful clinical importance. Late bowel side effects (RTOGX2) were seen more commonly in the 74 Gy and 1.5 cm margin groups (P ¼ 0.02 and P ¼ 0.05, respectively) in the first 2 years after randomisation. Similar results were found using the LENT SOM assessments. No significant differences in late bladder side effects were seen between the randomised groups using the RTOG scoring system. Using the LENT SOM instrument, a higher proportion of men treated in the 74 Gy group had Grade X3 urinary frequency at 6 and 12 months. Compared to baseline scores, bladder symptoms improved after 6 months or more follow-up in all groups. Sexual function d...

show abstract

Section: Discussionsupporting

confidence: 79%

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The LENT-SOMA scales are not yet fully validated, however, the scales have been compared with other scoring systems for late radiation effects in CCSs, 33 showing good correlation for bladder and rectum complications. In this study, we have used the subjective scale, where intestinal, urinary and skeletal problems (pain) are covered by 27 items.…”

Section: Methodsmentioning

confidence: 99%

Chronic fatigue and its correlates in long‐term survivors of cervical cancer treated with radiotherapy

Vistad

Fosså

Kristensen

et al. 2007

BJOG

View full text Add to dashboard Cite

Objective To describe the prevalence of chronic fatigue (CF) and associated variables in locoregional cervical cancer survivors (CCSs) surveyed >5 years after radiotherapy. Demographic, clinical and psychological characteristics of the CCSs were compared with normative data.Design Cross-sectional study.Setting Department of Gynaecologic Oncology at RikshospitaletRadiumhospitalet Medical Center, Oslo, Norway.Population Seventy-nine CCSs aged £79 years, treated between 1994 and 1999, representing 62% of those invited. Normative data were based on various population studies of Norwegian women.Methods Data were collected by means of a mailed questionnaire, which included demographic variables and instruments covering fatigue, mental distress, sexual functioning, somatic impairments and quality of life (QOL).Main outcome measures Self-reported fatigue score and caseness of CF based on the fatigue questionnaire.Results CCSs showed 30% CF versus 13% reported in the general population (P = 0.001). CCSs with CF had a significantly lower QOL, higher levels of anxiety and depression and more physical impairments than those without CF. In a multivariable regression model, depression was the only variable significantly associated with CF in CCSs.Conclusions More CCSs have CF than age-matched women in the general population. CF should be of clinical concern since these women also frequently have treatable mental and physical problems.

show abstract

“…Most studies refer to the EORTC/RTOG-CTC score (Common Toxicity Criteria), which is easy to use and has been validated by various clinical trials [1,3,5,7,10,12,15,17,19,20]. The purpose of this investigation was to compare subjective CTC skin scores with objective spectrophotometric color measurements of the skin in patients irradiated for early-stage breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Spectrophotometric Skin Measurements Correlate with EORTC/RTOG-Common Toxicity Criteria

et al. 2005

View full text Add to dashboard Cite

show abstract

Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems

Cited by 53 publications

References 11 publications

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

Chronic fatigue and its correlates in long‐term survivors of cervical cancer treated with radiotherapy

Spectrophotometric Skin Measurements Correlate with EORTC/RTOG-Common Toxicity Criteria

Contact Info

Product

Resources

About